Drug Profile
Research programme: Rett syndrome therapeutics - Rett Syndrome Research Trust/Q-State Biosciences
Latest Information Update: 28 Aug 2021
Price :
$50
*
At a glance
- Originator Q-State Biosciences; Rett Syndrome Research Trust
- Class Gene therapies; Proteins; Stem cell therapies
- Mechanism of Action Cell replacements; Gene transference; Protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Rett syndrome
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for research development in Rett syndrome in USA
- 18 Jul 2017 Early research in Rett syndrome in USA (unspecified route)